Evidence map›Paper›PMID 30173305›Full record

ReviewCurrent rheumatology reports2018

A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.

Peter K K Wong, Hanish Bagga, Claire Barrett, Geoff Chong, Patrick Hanrahan, Teja Kodali, Mona Marabani, H Miles Prince, John Riordan, Phillip Swarbrick and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Peter K K WongMid-North Coast Arthritis Clinic, Coffs Harbour, New South Wales, Australia. pkkw12@gmail.com.
Hanish BaggaMid-North Coast Arthritis Clinic, Coffs Harbour, New South Wales, Australia.
Claire BarrettRedcliffe Hospital, Redcliffe, Queensland, Australia.
Geoff ChongOlivia Newton John Cancer, Wellness & Research Centre, Austin Health, Heidelberg, Victoria, Australia.
Patrick HanrahanPrivate Rheumatology practice, South Perth, Western Australia, Australia.
Teja KodaliMid-North Coast Arthritis Clinic, Coffs Harbour, New South Wales, Australia.
Mona MarabaniCampsie Rheumatology Clinic and Canterbury Hospital, Sydney, New South Wales, Australia.
H Miles PrinceMolecular Oncology and Cancer Immunology, Epworth Healthcare, Richmond, Victoria, Australia.
John RiordanIllawarra Rheumatology and University of Wollongong Graduate School of Medicine, Wollongong, New South Wales, Australia.
Phillip SwarbrickPrivate Dermatology Practice, Burswood, Western Australia, Australia.
Ray WhitePrivate Rheumatology Practice, Campbelltown, New South Wales, Australia.
Laurel YoungRedcliffe Hospital, Redcliffe, Queensland, Australia.
Arthritis Australia · AURedcliffe Hospital · AUAustin Health · AUCamden and Campbelltown Hospitals · AUCanterbury Hospital · AURoyal Prince Alfred Hospital · AUUniversity of Melbourne · AUUniversity of Western Australia · AUUniversity of Wollongong · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewConventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) have been used in the treatment of inflammatory arthritis (IA) for many years. More recently, biologic (bDMARDs) and targeted synthetic (tsDMARDs) DMARDs have further improved treatment. Due to increased patient longevity and effective oncology treatment, rheumatologists often encounter patients with IA and previous malignancy. The immunosuppressive effect of DMARDs causes concern regarding impaired tumour surveillance with a potential increased risk of malignancy. We reviewed the literature regarding the risk of malignancy in patients on cs-/b-/tsDMARDS and sought to provide practical advice regarding use of these drugs in patients with previous malignancy. RECENT

findingsData from randomised controlled trials is limited as patients with pre-existing malignancy are often excluded. Reassuringly, an increasing range of "real world" data from various national b/tsDMARD registries has not provided a convincing signal that these drugs increase tumour recurrence. Nevertheless, awareness of, and adherence to, national screening guidelines for malignancy is important. Given the improvement in quality of life achieved with these novel and well-tolerated therapeutic agents, the benefit/risk profile remains overwhelmingly favourable in most patients.

Indexed as

Practice Patterns, Physicians'Antirheumatic AgentsArthritis, RheumatoidBiological ProductsHumansNeoplasmsQuality of LifeAntirheumatic AgentsBiological ProductsbDMARDsBiologicsCancercsDMARDsDisease modifying anti-rheumatic drugsMalignancytsDMARDs

Identifiers

PMID30173305
OpenAlexW2889023273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.